The granting of aid for the implementation of an investment plan to the investment body “THERACELL LABORATORIES IKE” was approved, with a total supported cost of 82,916,661 euros. The investment plan has been classified as a strategic investment.
According to the decision signed by Deputy Minister of Development and Investments Nikos Papathanasis, the investment concerns the clinical development and application of advanced autologous (the patient is the cell donor) cell and gene therapies, the production of which will be carried out near the treatment centers, within specially configured autonomous production OMPUL (Orgenesis Mobile Processing Unit Laboratories) units with the application of the decentralized POCare (Point of Care) model, i.e. the development, production and administration of CGTs (Cell & Gene Therapies) close to the patient.
The object
As noted, the object of the investment is an initial investment in a new economic activity and includes:
a. the installation of OMPULs within the surrounding area, near the point of patient hospitalization, of selected hospitals that have the required space,
b. the completion of industrial research and automation of OMPULs for mass production of treatments,
c. the experimental development of treatments through clinical trials within the framework of the approval process which will concern the testing and documentation of new products in an environment of real conditions of diseases and hospitalization, and
d. the production and distribution of new cell and gene therapies.
Plan
The investment plan of “THERACELL LABORATORIES IKE” was characterized, by decision of the Interministerial Committee for Strategic Investments was included in the “Strategic Investments 2” category, i.e. strategic investments which create in a sustainable way at least 50 new Annual Work Units (AWU) and their total budget is greater than 30,000,000 euros, according to the relevant legal provisions. That is, the approved aid falls under the category of regional investment aid and the category of aid for research and development projects.
Read also: Strategic Investments: The Selection Process, Duties and Fees of Auditors
The beneficiary of the aid is the company under the name “THERACELL LABORATORIES IKE” in which “THERACELL ADVANCED BIOTECHNOLOGICAL APPLICATIONS SOLE REPRESENTATIVE COMPANY” and ORGENESIS MARYLAND INC each participate by 50%.
The corporate capital of the investment entity at the time of submission of the affiliation application amounts to 25,000 euros.
Cost of investment plan
The subsidized expenses that were accepted upon the recommendation of “Enterprise Greece”, based on the submitted investment file, are divided into investment expenses, amounting to 4,349,603 euros, and expenses for research and development, amounting to 78,567,058 euros. The total cost of the investment project amounts to 82,916,661 euros.
Aid provided
– Tax Incentives
The incentive of tax exemption for the enhanced costs of the laboratory in Corinth and the 7 OMPULs of the investment plan, amounting to 4,349,603.00 euros, is debited. The amount of the granted tax exemption aid amounts to 1,957,321 euros, i.e. 45% of the total expenditure for which aid is granted.
– Aid for research and development
The incentive of the grant for research and development projects for the enhanced costs of experimental development, industrial research and feasibility studies of the investment plan, amounting to 78,567,058 euros, is debited. The amount of the given grant for research and development costs amounts to 31,728,747 euros.
Funding sources
The financial structure of the investment plan is analyzed by funding source as follows:
A. Equity
– Increase in corporate capital of 4,145,833 euros
B. External financing
– Bond loan of 37,000,000 euros
– Bank loan of 10,042,081 euros
Total Own Participation 51,187,914 euros
The investment body’s own participation, whether through equity or external financing, must not contain any state aid, public support, or provision.
The amount of funds per funding source will be determined precisely upon completion of the investment plan and will be calculated at this actual cost.
Conditions for granting said aid
The support of the investment plan is approved on the condition that the investment entity complies with the following conditions.
1. Place of installation
The investment will be implemented in a leased industrial property at the 80th km of Athens – Corinth highway, in the Municipality of Corinth, where a research and development laboratory for future treatments will be built.
The autonomous production units (OMPULs) will be temporarily placed in selected areas within or near hospitals and in any case closer to the point of patient hospitalization. The investment body is obliged, during the implementation control of the investment, to provide documents for the use of the plots on which the above autonomous production units will be installed.
2. Dependent job positions
The investment body is a newly established company and at the time of submission of the application for inclusion in the procedures of Law 4608/2019 did not employ any staff.
The new positions that will be created from the first year of full operation of the investment amount to 174 annual work units.
The application submission date is May 7, 2021, which is also the date on which the start of work on the investment plan can take place, and the completion of the investment plan is set for December 31, 2026.
Among the obligations of the investment implementing body is that it must comply with the long-term obligations after the completion of the investment plan and the certification of the start of production for a period of 3 years.
Latest News
IRIS: Deadline Approaches for Freelancers to Register
It should be noted that there is a daily 500 euros transaction limit via IRIS per customer with this limit not applying to the total payments a professional can receive in a 24-hour period.
PPC Partners Up to Boost Renewable Energy Capacity in Greece
This is a move that aims for the gradual phase-out of lignite units and an increase in renewable energy sources, with a particular emphasis on wind energy
Mitsotakis Calls on Greek-Americans to Invest in Greece
The Greek PM emphasized the strategic depth of the relationship between Greece and the United States, a long-standing friendship unaffected by who's in the White House
Greece’s Major Tourist Markets Balk at €20 Tourist Tax Plans
UK tabloids highlight PM Mitsotakis' plans to combat overtourism through a steep new tourist tax on popular destinations. Meanwhile, Germany warns that the move could drive their tourists to Spain and Italy.
Kaspersky: Global Study Highlights Rise of Revenge Porn
Additionally, 11.29% of men of the sample confessed to sharing intimate images they received with others without consent
EC Approves Alexandroupolis FSRU Terminal
The LNG Terminal in Alexandroupolis is expected to begin commercial operations on October 1, 2024.
Athens Stock Exchange Launches Roadshows to Boost Liquidity and Attract New Listings
2025 will commence with an event hosted by JP Morgan in New York, where the Greek stock market 'blue chips' will be represented
RRF: Greece Slow to Absorb Funds, Slower to Disclose Recipients
A report at IN.gr points out that less than 1/4th of RRF loans have reached their intended recipients, and only Greece and Bulgaria are 'late' on disclosing information on actual recipients of RRF funds.
Greece’s Organized Food Sector Challenged. Retailers Fear Rev Declines
According to a major retailer there has been negative inflation in the sector in recent months and that any development must exclusively come from a volume increase.
EU Organic Day 2024: Greece’s Organic Farming Sector on the Rise
Celebrated annually on September 23, Greece, which is seeing significant growth in its organic sector, will host events at Syntagma Square from 9 am to 3 pm